{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:29:47Z","timestamp":1792920587029,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Synthetic long peptides (SLPs) are a promising vaccine modality that exploit dendritic cells (DC) to treat chronic infections or cancer. Currently, the design of SLPs relies on in silico prediction and multifactorial T cells assays to determine which SLPs are best cross-presented on DC human leukocyte antigen class I (HLA-I). Furthermore, it is unknown how TLR ligand-based adjuvants affect DC cross-presentation. Here, we generated a unique, high-quality immunopeptidome dataset of human DCs pulsed with 12 hepatitis B virus (HBV)-based SLPs combined with either a TLR1\/2 (Amplivant\u00ae) or TLR3 (PolyI:C) ligand. The obtained immunopeptidome reflected adjuvant-induced differences, but no differences in cross-presentation of SLPs. We uncovered dominant (cross-)presentation on B-alleles, and identified 33 unique SLP-derived HLA-I peptides, several of which were not in silico predicted and some were consistently found across donors. Our work puts forward DC immunopeptidomics as a valuable tool for therapeutic vaccine design.<\/jats:p>","DOI":"10.1038\/s41541-025-01069-1","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T08:45:35Z","timestamp":1737189935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design"],"prefix":"10.1038","volume":"10","author":[{"given":"Amy L.","family":"Kessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel F. A.","family":"Pieterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter A. S.","family":"Doff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Bezstarosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Bouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Klarenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diahann T. S. L.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbie J.","family":"Luijten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8757-9611","authenticated-orcid":false,"given":"Jeroen A. A.","family":"Demmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7907-8315","authenticated-orcid":false,"given":"Sonja I.","family":"Buschow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"1069_CR1","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","volume":"37","author":"KL Rock","year":"2016","unstructured":"Rock, K. L., Reits, E. & Neefjes, J. Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 37, 724\u2013737 (2016).","journal-title":"Trends Immunol."},{"key":"1069_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0093-7754(03)00231-8","volume":"30","author":"N Berinstein","year":"2003","unstructured":"Berinstein, N. Overview of therapeutic vaccination approaches for cancer. Semin Oncol. 30, 1\u20138 (2003).","journal-title":"Semin Oncol."},{"key":"1069_CR3","doi-asserted-by":"publisher","first-page":"32228","DOI":"10.18632\/oncotarget.4772","volume":"6","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf, E. M. et al. A phase 1\/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget 6, 32228\u201332243 (2015).","journal-title":"Oncotarget"},{"key":"1069_CR4","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-22-3361","volume":"29","author":"KCM Gosens","year":"2023","unstructured":"Gosens, K. C. M. et al. Therapeutic vaccination against human papillomavirus type 16 for the treatment of high-grade anal intraepithelial neoplasia in HIV+ men. Clin. Cancer Res. 29, 4109\u20134117 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1069_CR5","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","volume":"22","author":"MI van Poelgeest","year":"2016","unstructured":"van Poelgeest, M. I. et al. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar\/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clin. Cancer Res. 22, 2342\u20132350 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1069_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"1069_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1069_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1069_CR9","doi-asserted-by":"publisher","first-page":"7855","DOI":"10.1073\/pnas.93.15.7855","volume":"93","author":"RE Toes","year":"1996","unstructured":"Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. & Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93, 7855\u20137860 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1069_CR10","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.4049\/jimmunol.156.10.3911","volume":"156","author":"RE Toes","year":"1996","unstructured":"Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M. & Melief, C. J. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156, 3911\u20133918 (1996).","journal-title":"J. Immunol."},{"key":"1069_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163118","volume":"14","author":"D Jansen","year":"2023","unstructured":"Jansen, D. et al. Induction of broad multifunctional CD8+ and CD4+ T cells by hepatitis B virus antigen-based synthetic long peptides ex vivo. Front Immunol. 14, 1163118 (2023).","journal-title":"Front Immunol."},{"key":"1069_CR12","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/eji.201343324","volume":"43","author":"RA Rosalia","year":"2013","unstructured":"Rosalia, R. A. et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur. J. Immunol. 43, 2554\u20132565 (2013).","journal-title":"Eur. J. Immunol."},{"key":"1069_CR13","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","volume":"179","author":"MS Bijker","year":"2007","unstructured":"Bijker, M. S. et al. CD8+ CTL priming by exact peptide epitopes in incomplete Freund\u2019s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179, 5033\u20135040 (2007).","journal-title":"J. Immunol."},{"key":"1069_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-013-1499-2","volume":"63","author":"PJ de Vos van Steenwijk","year":"2014","unstructured":"de Vos van Steenwijk, P. J. et al. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol. Immunother. 63, 147\u2013160 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"1069_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","volume":"5","author":"E Massarelli","year":"2019","unstructured":"Massarelli, E. et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol. 5, 67\u201373 (2019).","journal-title":"JAMA Oncol."},{"key":"1069_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med 27, 515\u2013525 (2021).","journal-title":"Nat. Med"},{"key":"1069_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1069_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10661-8","volume":"10","author":"T Wu","year":"2019","unstructured":"Wu, T. et al. Quantification of epitope abundance reveals the effect of direct and cross-presentation on influenza CTL responses. Nat. Commun. 10, 2846 (2019).","journal-title":"Nat. Commun."},{"key":"1069_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst, J., Ahrends, T., Babala, N., Melief, C. J. M. & Kastenmuller, W. CD4(+) T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635\u2013647 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1069_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245\u2013252 (1998).","journal-title":"Nature"},{"key":"1069_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1021\/pr9008546","volume":"9","author":"SI Buschow","year":"2010","unstructured":"Buschow, S. I. et al. Dominant processes during human dendritic cell maturation revealed by integration of proteome and transcriptome at the pathway level. J. Proteome Res. 9, 1727\u20131737 (2010).","journal-title":"J. Proteome Res."},{"key":"1069_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/intimm\/dxh077","volume":"16","author":"R Rouas","year":"2004","unstructured":"Rouas, R. et al. Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. Int Immunol. 16, 767\u2013773 (2004).","journal-title":"Int Immunol."},{"key":"1069_CR23","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044\u20131066 (2020).","journal-title":"Cell"},{"key":"1069_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front Immunol. 5, 461 (2014).","journal-title":"Front Immunol."},{"key":"1069_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target Ther. 8, 283 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1069_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","volume":"239","author":"MS Duthie","year":"2011","unstructured":"Duthie, M. S., Windish, H. P., Fox, C. B. & Reed, S. G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239, 178\u2013196 (2011).","journal-title":"Immunol. Rev."},{"key":"1069_CR27","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.3389\/fimmu.2018.02874","volume":"9","author":"NI Ho","year":"2018","unstructured":"Ho, N. I., Huis In \u2018t Veld, L. G. M., Raaijmakers, T. K. & Adema, G. J. Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? Front Immunol. 9, 2874 (2018).","journal-title":"Front Immunol."},{"key":"1069_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545\u2013558 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1069_CR29","doi-asserted-by":"publisher","unstructured":"de Beijer, M. T. A. et al. Discovery and selection of hepatitis B virus-derived T cell epitopes for global immunotherapy based on viral indispensability, conservation, and HLA-binding strength. J. Virol. 94 https:\/\/doi.org\/10.1128\/jvi.01663-19 (2020).","DOI":"10.1128\/jvi.01663-19"},{"key":"1069_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/infdis\/jix614","volume":"217","author":"Y Dou","year":"2018","unstructured":"Dou, Y. et al. HBV-derived synthetic long peptide can boost CD4+ and CD8+ T-cell responses in chronic HBV patients ex vivo. J. Infect. Dis. 217, 827\u2013839 (2018).","journal-title":"J. Infect. Dis."},{"key":"1069_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s40425-018-0455-2","volume":"6","author":"GG Zom","year":"2018","unstructured":"Zom, G. G. et al. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication. J. Immunother. Cancer 6, 146 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1069_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2014.09.010","volume":"146","author":"R Ammi","year":"2015","unstructured":"Ammi, R. et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharm. Ther. 146, 120\u2013131 (2015).","journal-title":"Pharm. Ther."},{"key":"1069_CR33","doi-asserted-by":"publisher","unstructured":"Niemi, J. V. L., Sokolov, A. V. & Schioth, H. B. Neoantigen vaccines; clinical trials, classes, indications, adjuvants and combinatorial treatments. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14205163 (2022).","DOI":"10.3390\/cancers14205163"},{"key":"1069_CR34","doi-asserted-by":"publisher","first-page":"104746","DOI":"10.1016\/j.antiviral.2020.104746","volume":"178","author":"Y Dou","year":"2020","unstructured":"Dou, Y. et al. Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients. Antivir. Res. 178, 104746 (2020).","journal-title":"Antivir. Res."},{"key":"1069_CR35","doi-asserted-by":"publisher","first-page":"100576","DOI":"10.1016\/j.jhepr.2022.100576","volume":"4","author":"MTA de Beijer","year":"2022","unstructured":"de Beijer, M. T. A. et al. Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma. JHEP Rep. 4, 100576 (2022).","journal-title":"JHEP Rep."},{"key":"1069_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005725","volume":"13","author":"M Bassani-Sternberg","year":"2017","unstructured":"Bassani-Sternberg, M. et al. Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Comput Biol. 13, e1005725 (2017).","journal-title":"PLoS Comput Biol."},{"key":"1069_CR37","doi-asserted-by":"publisher","unstructured":"Bouzid, R. et al. Empirical evaluation of the use of computational HLA binding as an early filter to the mass spectrometry-based epitope discovery workflow. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13102307 (2021).","DOI":"10.3390\/cancers13102307"},{"key":"1069_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201800357","volume":"19","author":"M Andreatta","year":"2019","unstructured":"Andreatta, M. et al. MS-Rescue: a computational pipeline to increase the quality and yield of immunopeptidomics experiments. Proteomics 19, e1800357 (2019).","journal-title":"Proteomics"},{"key":"1069_CR39","doi-asserted-by":"publisher","first-page":"100515","DOI":"10.1016\/j.mcpro.2023.100515","volume":"22","author":"M Shahbazy","year":"2023","unstructured":"Shahbazy, M. et al. Benchmarking bioinformatics pipelines in data-independent acquisition mass spectrometry for immunopeptidomics. Mol. Cell Proteom. 22, 100515 (2023).","journal-title":"Mol. Cell Proteom."},{"key":"1069_CR40","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.18632\/aging.203053","volume":"13","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. Identification of novel hepatitis B virus therapeutic vaccine candidates derived from polymerase protein. Aging (Albany NY) 13, 14372\u201314384 (2021).","journal-title":"Aging (Albany NY)"},{"key":"1069_CR41","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/eji.1830230603","volume":"23","author":"HW Nijman","year":"1993","unstructured":"Nijman, H. W. et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23, 1215\u20131219 (1993).","journal-title":"Eur. J. Immunol."},{"key":"1069_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4049\/jimmunol.1901173","volume":"205","author":"A Sachs","year":"2020","unstructured":"Sachs, A. et al. Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells. J. Immunol. 205, 539\u2013549 (2020).","journal-title":"J. Immunol."},{"key":"1069_CR43","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3389\/fimmu.2020.01981","volume":"11","author":"F Marino","year":"2020","unstructured":"Marino, F. et al. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference. Front Immunol. 11, 1981 (2020).","journal-title":"Front Immunol."},{"key":"1069_CR44","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00262-010-0833-1","volume":"59","author":"G Schreibelt","year":"2010","unstructured":"Schreibelt, G. et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 59, 1573\u20131582 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"1069_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1069_CR46","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1021\/acs.bioconjchem.7b00808","volume":"29","author":"BJ Ignacio","year":"2018","unstructured":"Ignacio, B. J., Albin, T. J., Esser-Kahn, A. P. & Verdoes, M. Toll-like Receptor Agonist Conjugation: A Chemical Perspective. Bioconjug Chem. 29, 587\u2013603 (2018).","journal-title":"Bioconjug Chem."},{"key":"1069_CR47","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nature04596","volume":"440","author":"JM Blander","year":"2006","unstructured":"Blander, J. M. & Medzhitov, R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808\u2013812 (2006).","journal-title":"Nature"},{"key":"1069_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940047","volume":"13","author":"W Lee","year":"2022","unstructured":"Lee, W. & Suresh, M. Vaccine adjuvants to engage the cross-presentation pathway. Front Immunol. 13, 940047 (2022).","journal-title":"Front Immunol."},{"key":"1069_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42668-7","volume":"14","author":"J Chiaro","year":"2023","unstructured":"Chiaro, J. et al. Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors. Nat. Commun. 14, 7056 (2023).","journal-title":"Nat. Commun."},{"key":"1069_CR50","doi-asserted-by":"publisher","unstructured":"Olson, E., Ceccarelli, T. & Raghavan, M. Endo-lysosomal assembly variations among human leukocyte antigen class I (HLA class I) allotypes. Elife 12 https:\/\/doi.org\/10.7554\/eLife.79144 (2023).","DOI":"10.7554\/eLife.79144"},{"key":"1069_CR51","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.4049\/jimmunol.1403234","volume":"194","author":"R Apps","year":"2015","unstructured":"Apps, R. et al. Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells. J. Immunol. 194, 3594\u20133600 (2015).","journal-title":"J. Immunol."},{"key":"1069_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212136","volume":"14","author":"CA Brito-Sierra","year":"2023","unstructured":"Brito-Sierra, C. A., Lannan, M. B., Malherbe, L. P. & Siegel, R. W. The HLA class I immunopeptidomes of AAV capsid proteins. Front Immunol. 14, 1212136 (2023).","journal-title":"Front Immunol."},{"key":"1069_CR53","doi-asserted-by":"publisher","unstructured":"Yarzabek, B. et al. Variations in HLA-B cell surface expression, half-life and extracellular antigen receptivity. Elife 7. https:\/\/doi.org\/10.7554\/eLife.34961 (2018).","DOI":"10.7554\/eLife.34961"},{"key":"1069_CR54","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1069_CR55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri3254","volume":"12","author":"OP Joffre","year":"2012","unstructured":"Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557\u2013569 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1069_CR56","doi-asserted-by":"publisher","unstructured":"Blander, J. M., Yee Mon, K. J., Jha, A., & Roycroft, D. The show and tell of cross-presentation. Adv. Immunol.. https:\/\/doi.org\/10.1016\/bs.ai.2023.08.002 (2023).","DOI":"10.1016\/bs.ai.2023.08.002"},{"key":"1069_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","volume":"109","author":"DA Ferrington","year":"2012","unstructured":"Ferrington, D. A. & Gregerson, D. S. Immunoproteasomes: structure, function, and antigen presentation. Prog. Mol. Biol. Transl. Sci. 109, 75\u2013112 (2012).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"1069_CR58","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/hep.20614","volume":"41","author":"S Urbani","year":"2005","unstructured":"Urbani, S. et al. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV\/HCV coinfection. Hepatology 41, 826\u2013831 (2005).","journal-title":"Hepatology"},{"key":"1069_CR59","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1084\/jem.181.3.1047","volume":"181","author":"B Rehermann","year":"1995","unstructured":"Rehermann, B. et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 181, 1047\u20131058 (1995).","journal-title":"J. Exp. Med."},{"key":"1069_CR60","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.4049\/jimmunol.1600808","volume":"197","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg, M. & Gfeller, D. Unsupervised HLA peptidome deconvolution improves ligand prediction accuracy and predicts cooperative effects in peptide-HLA interactions. J. Immunol. 197, 2492\u20132499 (2016).","journal-title":"J. Immunol."},{"key":"1069_CR61","doi-asserted-by":"publisher","unstructured":"Winter, M. B. et al. Immunoproteasome functions explained by divergence in cleavage specificity and regulation. Elife 6. https:\/\/doi.org\/10.7554\/eLife.27364 (2017).","DOI":"10.7554\/eLife.27364"},{"key":"1069_CR62","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1021\/pr200621z","volume":"10","author":"ML Biniossek","year":"2011","unstructured":"Biniossek, M. L., Nagler, D. K., Becker-Pauly, C. & Schilling, O. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J. Proteome Res. 10, 5363\u20135373 (2011).","journal-title":"J. Proteome Res."},{"key":"1069_CR63","doi-asserted-by":"publisher","unstructured":"Marzella, D. F. et al. Improving generalizability for MHC-I binding peptide predictions through geometric deep learning. bioRxiv. https:\/\/doi.org\/10.1101\/2023.12.04.569776 (2024).","DOI":"10.1101\/2023.12.04.569776"},{"key":"1069_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1210044","volume":"14","author":"L Buonaguro","year":"2023","unstructured":"Buonaguro, L. & Tagliamonte, M. Peptide-based vaccine for cancer therapies. Front Immunol. 14, 1210044 (2023).","journal-title":"Front Immunol."},{"key":"1069_CR65","doi-asserted-by":"crossref","unstructured":"Kuznetsova, K. G., Solovyeva, E. M., Kuzikov, A. V., Gorshkov, M. V. & Moshkovskii, S. A. [Modification of cysteine residues for mass spectrometry-based proteomic analysis: facts and artifacts] Modifikatsiia ostatkov tsisteina dlia mass-spektrometricheskogo proteomnogo analiza: fakty i artefakty. Biomed Khim 66, 18\u201329 (2020).","DOI":"10.18097\/pbmc20206601018"},{"key":"1069_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847105","volume":"13","author":"Y Ding","year":"2022","unstructured":"Ding, Y. et al. Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes. Front Immunol. 13, 847105 (2022).","journal-title":"Front Immunol."},{"key":"1069_CR67","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","volume":"14","author":"AW Purcell","year":"2019","unstructured":"Purcell, A. W., Ramarathinam, S. H. & Ternette, N. Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nat. Protoc. 14, 1687\u20131707 (2019).","journal-title":"Nat. Protoc."},{"key":"1069_CR68","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.4049\/jimmunol.157.9.3850","volume":"157","author":"WF Pickl","year":"1996","unstructured":"Pickl, W. F. et al. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J. Immunol. 157, 3850\u20133859 (1996).","journal-title":"J. Immunol."},{"key":"1069_CR69","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.immuni.2012.10.018","volume":"38","author":"E Segura","year":"2013","unstructured":"Segura, E. et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 38, 336\u2013348 (2013).","journal-title":"Immunity"},{"key":"1069_CR70","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2337\/db15-1031","volume":"65","author":"M van Lummel","year":"2016","unstructured":"van Lummel, M. et al. Discovery of a selective islet peptidome presented by the highest-risk HLA-DQ8trans molecule. Diabetes 65, 732\u2013741 (2016).","journal-title":"Diabetes"},{"key":"1069_CR71","doi-asserted-by":"publisher","unstructured":"Wickham, H. et al. Welcome to the Tidyverse. The Journal of Open Source Software 4. https:\/\/doi.org\/10.21105\/joss.01686 (2019).","DOI":"10.21105\/joss.01686"},{"key":"1069_CR72","unstructured":"Glue: Interpreted String Literals (2022)."},{"key":"1069_CR73","unstructured":"Conflicted: An Alternative Conflict Resolution Strategy (2023)."},{"key":"1069_CR74","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1069_CR75","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559\u2013575 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"1069_CR76","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1093\/bioinformatics\/bts479","volume":"28","author":"JI Goldstein","year":"2012","unstructured":"Goldstein, J. I. et al. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. Bioinformatics 28, 2543\u20132545 (2012).","journal-title":"Bioinformatics"},{"key":"1069_CR77","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41588-021-00935-7","volume":"53","author":"Y Luo","year":"2021","unstructured":"Luo, Y. et al. A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. Nat. Genet. 53, 1504\u20131516 (2021).","journal-title":"Nat. Genet."},{"key":"1069_CR78","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molimm.2010.11.004","volume":"48","author":"KM Miles","year":"2011","unstructured":"Miles, K. M., Miles, J. J., Madura, F., Sewell, A. K. & Cole, D. K. Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Mol. Immunol. 48, 728\u2013732 (2011).","journal-title":"Mol. Immunol."},{"key":"1069_CR79","unstructured":"R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2023)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01069-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T09:28:25Z","timestamp":1737192505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01069-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01069-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4384370\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. and D.J. are listed as inventors on a patent application related to the work in this manuscripts on novel long peptide antigens for treatment of hepatitis B related disease, filed by ISA pharmaceuticals B.V. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}